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1 Narratives and cancer patients 
 
The management of patients with long-term conditions is one of the major 
challenges facing healthcare systems worldwide (United Nations General Assembly 
2013). A long-term condition is a condition for which there is no cure; rather, long-
term conditions must be managed through a range of treatment options including 
drugs (King’s Fund 2012). Long-term conditions include diabetes, hypertension, 
chronic kidney disease and cancer, and management accounts for a substantial 
proportion of health service resources. For example, in the UK long-term condition 
patients account for 30% of the patient population and 70% of the healthcare 
spend (Department of Health 2012). 
 
Patients living with long-term conditions play an important role in management of 
their condition, and Coulter et al. (2015) provide a comprehensive review of the 
role of personal care planning in the management of long-term conditions. They 
describe personal care planning as a “collaborative process used in chronic 
condition management in which patients and clinicians identify and discuss 
problems caused by or related to the patient’s condition, and develop a plan for 
tackling these” (Coulter et al. 2015). For personal care planning to be effective, 
patients must be supported in the difficult decisions they make in respect of 
lifestyle choices and treatment options. 
 
Cancer is one of the fastest rising long-term conditions (Department of Health 
2012). Cancer is one of the leading causes of death worldwide, with approximately 
8 million deaths recorded in 2012 and a 70% rise in new cases expected over the 
next 20 years (Stewart & Wild 2014). Narrative has been shown to have value in 
the prevention of cancer through effective communication of risk. Janssen et al. 
(2013) provide a useful review of narrative in healthcare, noting that “by providing 
vivid information about the antecedents and the consequences of a health 
problem, narrative health information improves the extent to which people are 
able to imagine themselves developing a certain disease, which in turn may 
influence their risk judgments” (Janssen et al. 2013). Their own study explored the 
effects of risk communication to regular sunbed users in narrative and non-
narrative forms. Results showed that, compared with non-narrative information 
forms, narrative information promoted an increased feeling of skin cancer risk with 
respect to sunbed use in participants, and participants could more readily image 
themselves developing skin cancer. 
 
Narration can also support patients when making decisions on treatment options. 
Shaffer et al. (2013) report on the effect of process-focused and experience-
focused narratives on the patient decision-making process. Process narratives are 
designed to “prime participants to follow a particular decision process …[and] 
would most commonly entail patients considering additional dimensions of the 
decision process that they might not have considered otherwise” Shaffer et al. 
(2013). Experience narratives are designed to “increase knowledge and the 
perceived ability to imagine future health states … [which] could result in increased 
decisional satisfaction and an improved ability to make affective forecasts (i.e. 
forecasts of future feelings)” Shaffer et al. (2013). Importantly, neither process or 
experience narratives are thought to bias healthcare decisions, but to promote 
consideration of a broader set of issues than they might have otherwise or 
improve understanding of treatment outcome respectively. Focusing on breast 
cancer treatment decisions, and through a carefully designed test with control 
conditions, results of the study revealed that participants exposed to process-
focused narratives spent more time searching for information relating to key 
aspects of treatment that were discussed in the narratives. Participants exposed to 
experience-focused narratives were more confident in and satisfied with their 
treatment decisions. 
 
We propose that narrative can also inform clinicians’ understanding of cancer. We 
base this proposition on the following observations: 1) cancer is a complex system; 
2) effective drug design depends on understanding that complex system; and 3) 
narratives can inform our understanding of complex systems. The remainder of 
this chapter explores this proposition by unpacking these three observations in 
turn. 
 
Section 2 considers cancer as a complex system. We unpack some of the 
complexities associated with cancer as a system of interacting cells in the context 
of normal tissue. We pay particular attention to one level of functioning in cancer 
cells – that of the intracellular signalling network that represents the biochemical 
interactions among different species in the cell. It is these biochemical interactions 
that ultimately dictate cell fate. 
 
Section 3 explores this signalling network in the context of anti-cancer drug 
targets. Because of their role in cell fate, some signalling network components 
provide potentially useful drug targets for anti-cancer therapy. However, these 
drug targets are situated in the context of a topologically complex and dynamic 
network, and we consider how anti-cancer drugs seek to restore normal 
functioning in cell signalling networks and explore how therapy design is impeded 
by the complexity of the cellular system. 
 
Section 4 sets out what narrative might offer to support the process of drug 
design, both providing an example of work done to date that might serve as a 
foundation for narrating complexity and speculating on the contribution of 
narrative to anti-cancer treatment.  In Conclusion we suggest possible ways of 




2 Cancer as a complex system 
 
Cancer is not a single disease; it is a broad class of diseases of over 200 types 
(Cancer Research UK 2016), characterised by functional dysregulations within and 
surrounding affected cells, tissues and organs (Bown et al. 2012) as outlined in 
subsequent sections. Cancer originates from the aberrant behaviour of a single cell 
or region of cells that over time gives rise to an observable anomalous tissue 
structure in the form of a tumour, and can progress to non-local spread through 
the blood stream or lymphatic system. 
 
Cancer is therefore an emergent system where local (cell) scale processes lead to 
system-scale patterns in local cell populations, tissue structures, organs and 
ultimately in the body as a whole. As explored below, those tissue patterns in turn 
impact cellular processes. Moreover, there is increasing awareness of the 
heterogeneities in cancer: tumours comprise multiple cell types; patterning in 
tissue is likewise heterogeneous. That cancer is emergent at multiple scales and 
highly heterogeneous makes treatment very challenging. 
 
In 2000, Hanahan and Weinburg (2000) set out six biological hallmarks of cancer 
that have helped frame investigations and interpretation of findings. Here, these 
hallmarks are only briefly outlined and indeed greatly simplified since they provide 
a contextual backdrop to the challenge of drug design. Hanahan and Weinburg 
(2000) provide a rich description of all six hallmarks for the interested reader. 
 
Normal cells regulate the processes of growth and division and pre-programmed 
cell death, responding to spatially and temporally structured external signals that 
cue the cell to grow and information on mechanical stresses from the environment 
and from other cells (note there are a wide range of other factors involved). In 
effect, external signals are read in through receptors on the cell wall and 
processed by the cell to drive behaviour. This cellular processing enables tissue to 
maintain consistent and properly functioning structures. 
 
Cancer arises from perturbations in the processing of these signals, and such 
perturbations can lead to cells that are not well regulated by external stimuli. This 
dysregulation can confer cells with the six hallmarks of cancer: 
- Increased proliferation, where cells divide far more frequently than they 
should; 
- Unsuppressed growth, where cancer cells can grow in structural forms 
inconsistent with normal tissue (e.g. where mechanical pressures are larger);  
- Resistance to cell death, a natural and pre-programmed mechanism to 
promote cell turnover and maintain a healthy population of cells; 
- Replicative immortality, through a combination of the above three 
hallmarks and through changes in the mechanisms cells use to control the 
number of possible divisions; 
- Sustained angiogenesis, meaning that cancerous tissue can encourage 
development of structures able to supply oxygen and nutrients; 
- Invasion and metastasis, where tumour masses can move into adjacent 
tissue and into distant regions by changing the physical coupling of cancer 
cells to their microenvironment. 
 
Tumours thus originate from and are sustained by dysregulations within the signal 
processing within the cell, which confer on that cell particular ecological and 
evolutionary advantages. The resulting pattern at the tissue scale is the emerging 
tumour of cancer cells in the environmental context of normal tissue. An important 
observation is that cross-scale feedback occurs through competition for resource 
and space. Resource competition occurs because there is limited oxygen and 
nutrients yet there are increasingly more cells in the developing cancerous tissue 
structure. This growth is occurring in a limited space and the mechanical stresses 
on cells caused by too much growth in too little space are converted into 
biochemical signals and can actually promote further signal transduction and these 
stresses drive proliferation over time (see Jaalouk and Lammerding 2009 for a 
review). 
 
Kreeger and Lauffenburger (2009) provide an excellent review on the challenges 
posed when trying to unravel both the origins and consequences of such 
dysregulation in cancer cells. A key observation is that cell behaviour is controlled 
by a mix of genetic alterations and environmental context, and that the “greatest 
amount of information concerning phenotypic behaviour resides in the realm 
comprehending both genomic and environmental effects: dynamic protein 
network operations” (Kreeger and Lauffenburger 2009). 
 
These protein networks, or signalling networks, provide a mechanistic connection 
between external signals received at the cell surface and the cell nucleus (Cooper 
2000). These signalling networks represent the biochemical species that interact to 
form new compounds in order to process external signals. The nodes in the 
network represent the compounds that are formed and broken down in space 
over time as the cell processes extracellular signals and it is the result of this 
processes that drives the behaviour of the cell. 
 
Signals propagate through these networks and cancerous behaviours, i.e. the 
hallmarks, are often associated with measurable differences in the proteins that 
make up these pathways. Accordingly, amongst the myriad of levels of 
organisation of cellular, tissue and environmental factors, signalling networks are a 
promising route for drug design. However, signalling networks attract complexities 
in of themselves. 
 
 
3 Signalling networks and anti-cancer drug design 
 
As noted above, signalling networks transduct external stimuli, including growth 
factors and anti-cancer drugs, for processing by the cell nucleus. Importantly, 
these networks do not operate in isolation; networks are interconnected and this 
complicates their study. 
 
Figure 1 (from Hu et al. 2013) is illustrative of such a network, and shows two key, 
interconnected signalling pathways that are implicated in some of the hallmarks of 
cancer: pre-programmed cell death, cell proliferation and cell growth. These 
pathways are regulated by growth factor receptors (HER2 and HER3 in Figure 1). 
These two receptors regulate signalling in the PI3K/PTEN/AKT and 
Ras/Raf/MEK/ERK pathways that control cell survival, growth and proliferation. The 
details of the molecular species that comprise this network are beyond the scope 
of this Chapter. Important here are several topological features that give rise to 
complex, emergent behaviours. Note these features are a defining property of 
many signalling networks in biological sciences (Bown et al. 2012) – complexity 
arising from network topology is prevalent and not limited to this exemplar 




Figure 1: Cellular signalling pathways (reproduced from Hu et al. 2013). The two 
pathways RAF/MEK/ERK (left hand side) and PI3K/PTEN/AKT (right hand side) are 
interconnected by element PP2A. RM1 shows a feedback loop. Additional cross-
talk is shown by RM3 and RM4. Numbers refer to the underlying equation set (see 
discussion on interactive media below). 
 
Figure 1 shows pathway cross-talk and feedback loops, within and between 
networks. Cross-talk is shown towards the centre of the network by the PP2A 
enzyme, a known regulator of a wide range of cellular processes. This enzyme is 
connected to the AKT-PIP3 complex, which drives cell survival and growth, and the 
MEK complex, implicated in cell proliferation and differentiation among other 
processes. A cell has a limited amount of PP2A at any one time and in this 
particular cross-talk example, an increase in signalling activity in one pathway that 
interacts with this limited amount of PP2A causes an inhibition of signalling activity 
in the other pathway. Cross-activation, rather than the cross-inhibition shown here, 
is also observed in other pathways. 
 
Signalling is further complicated by the feedback loops shown in the network 
(Figure 1, dotted lines). Feedback loops are another pervasive feature of biological 
networks. Feedback loops have a regulatory role in such networks, helping to keep 
some intracellular conditions constant in the face of any perturbation. This network 
describes oscillations in AKT and ERK signalling pathway outputs, and these 
oscillations can be controlled by varying the strengths of the feedback loops in the 
networks. 
 
These topological complexities on the one hand provide signalling networks with 
marked robustness to external stimuli, maintaining proper functioning in the face 
of noisy inputs, yet on the other hand confer exquisite sensitivity to key variations 
in those inputs. Accordingly, networks can be either sensitive or resistant to small 
changes in input signals: sensitivity means that small, localised changes can have a 
pronounced impact on non-local network functioning; resistance means that 
network functioning is resilient to such change. 
 
This emergent phenomenon has implications in anti-cancer drug design (see 
below) but also in cancer-associated mutations. Figure 2 (from Goltsov et al. 2014) 
shows the impact of a cancer-associated mutation on network sensitivity in the 
form of a heatmap. The heatmap shows the sensitivity of 19 different entities in the 
signalling network, where light grey indicates high sensitivity and dark grey 
indicates low sensitivity, i.e. resistance. In normal functioning (Column 1 in Figure 
2), the network sensitivity heatmap is mainly mid to light grey, indicating a network 
that is sensitive to change but not dramatically so. Mutations can be introduced 
into the model to represent biological mutations in the cell. One single mutation in 
a key network node results in a network that is largely insensitive to change 
(Column 3 in Figure 2 is mainly dark grey and black), i.e. a local change results in a 




Figure 2: Heatmap of sensitivity of different entities in the signalling network 
(adapted from Goltsov et al. 2014). Column 1 shows the network in normal 
functioning, and when an anti-cancer drug is applied the network increases in 
overall sensitivity (Column 2). When a cancer-associated mutation is introduced 
the network is insensitive without or with the anti-cancer drug (Columns 3 and 4 
respectively). The addition of a second drug in combination with the first (Columns 
5-8) restores sensitivity to the anti-cancer drug (Column 8).  
 
To complicate cellular signalling further still, there is an increasing awareness that 
the network topology itself is not fixed (Lee et al. 2012). The network topology 
represents the interactions among different species in the cell, and the network 
changes in structure over time. These changes occur because different parts of the 
network interconnect and disconnect as the cell responds to acquired mutations 
and significant changes to external stimuli such as anti-cancer drug treatments. For 
example a cell can become resistant to the effect of a drug through these 
changes. 
 
Anti-cancer drug treatments are typically in the form of a “targeted cancer 
therapy”, a kind of therapy that is designed to disrupt aberrant behaviour in 
cellular signalling networks, either in an effort to restore normal functioning or to 
at least suppress cancerous behaviours in cells, by targeting a particular node in 
the network. Drugs are typically designed in a single-target-single-drug paradigm 
(Medina-Franco et al. 2013), i.e. a drug is designed to target a specific site in a 
network. However, single therapies have had only limited success (Singer et al. 
2008), with patients either failing to respond at all or developing resistance to the 
drug effect over time. 
 
This is, in part, because the single therapies are acting in the context of a range of 
mechanisms that compensate for and adapt to perturbations (here, drug action): 
these mechanisms include cross-talk, feedback loops, differential sensitivities to 
change across the network and changes in network structure in response to drug 
action. This means that targeted therapies can impact beyond their point of 
application, and often in ways that are difficult to anticipate (Bown et al. 2016). 
These features then limit efficacy of any single therapy, and patient resistance to a 
drug is a key challenge in anti-cancer therapy design. 
 
There is increasing evidence from both in vitro and in vivo studies that 
combination therapy, i.e. therapy comprising more than one drug and so target 
more than one site in the network, is a promising route to overcome the challenge 
of drug resistance. This evidence base is growing continually (Chandarlapaty 2012; 
Chong and Jänne  
2013) but typically the way in which the drugs work together to deliver improved 
performance is not well understood (Goltsov et al. 2014). The rational design of 
combination therapy depends on a mechanistic understanding of those networks 
in terms of the individual components and the way in which those components 
interact, locally and non-locally. Rational design needs ways of integrating, often 
fragmented, data that together reflects the system as a whole, or at least some 
representative subset of that system, and of interpreting the results of that 
integration. 
 
The complexity of that integration provides an opportunity for computational 
models. Models can identify signalling network states that confer drug resistance 
or sensitivity and shed light on how to manage the transition from one state to the 
other through combination therapy e.g. (Goltsov et al. 2012), and propose 
mechanisms of combination therapy action to explain why in a model of drugs 
binding to signalling network nodes two drugs that are applied individually are 
ineffective yet when applied in combination and at the same time are effective in 
overcoming drug resistance (Kholodenko 2015). Thus models can contribute to 
rational drug design and in doing so help us understand signalling pathway 
complexities. 
 
This opportunity is, however, impeded by the computational – biological discipline 
divide. Biologists and clinicians readily understand simple models, but simple 
models cannot deliver value in the face of the complexities noted above. Models 
that represent sufficient complexity to help understand a signalling network can be 
challenging for biologists to first formulate and then interpret (Janes and 
Lauffenburger 2013). Janes and Lauffenburger (2013) provide a review of the value 
of such signalling network models for experimental cell biology. They highlight that 
key barriers are confusions relating to the purpose of the model, predictions from 
the model and the wide range of modelling approaches available. The purpose 
should be to – try to – explain specific phenomena observed in experimentation; 
predictions made are often in the context of assumptions especially relating to 
gaps in knowledge for parameters; the selected approach needs to take account 
of the purpose and the available knowledge. Indeed, our own work on CoSMoS 
(Stepney et al. 2011) provides a framework to address exactly these barriers. 
 
Going beyond this computational – biological discipline divide, the complexities in 
signalling networks run deeper than topology. Nodes, and combinations of nodes, 
in the network serve as switches, integrators and inhibitors, and the specific 
function of any given node or sub-network can be variable, contextualised by its 
inputs in a non-linear manner. Thus, non-linear components operate with variable 
function in complex networks. It then becomes impossible to describe system 
behaviour in linear and simple narrative. In fact, it has been suggested that rather 
than a node-centric view, it is likely that the dynamic features of the network itself 
might form the basis of drug targets rather than the network components (Behar 
et al. 2013). 
 
 
4 Towards narratives for anti-cancer drug design 
 
We have so far established the following: 
- Cancer is a complex system driven in part by aberrant cellular function; 
- Signalling networks are a useful level of detail at which to study cellular 
function, and are themselves complex; 
- Parts of those signalling networks can be targeted by anti-cancer drug 
therapies to seek to restore aberrant functioning; 
- The signalling network is dynamic in its reaction to drugs and mutations, 
and its structure can change over time; 
- Computational models can support our understanding of cell responses to 
drug action, including the various mechanisms of drug resistance; 
- Computational models that are of sufficient detail to represent mechanisms 
of resistance can be prohibitively complex for biologists. 
 
Here, we describe briefly an interactive visualisation technology that could provide 
the foundations for narratives. The use of data storytelling to communicate and 
stimulate insights is a growing research area (Bach et al. 2016). Segel and Heer 
(2010) provide a systematic review of work seeking to combine narrative and 
interactive visualisations, and note that while sophisticated visualisation tools might 
provide powerful vehicles for discovering stories narrative communication depends 
on more than visualisation.  
 
Boy et al. (2015) distinguish between two types of information visualisations: 
explanatory and exploratory. Explanatory information visualisations are common in 
journalistic contexts, are typically used to support the narrative presented in the 
text, and have limited interactivity. Segel and Heer (2010) categorise such 
explanatory information visualisations as author-driven. In contrast, exploratory 
information visualisations require a reader-driven approach with free interactivity 
(Boy et al. 2015), and are motivated by provoking discoveries in the patterns of 
data. 
 
We propose that our technology is a vehicle to support reader-driven narratives, 
but is not in of itself a narrative. This technology, SiViT (Bown et al. 2016), turns a 
complex model into an interactive animation, allowing the cancer specialist 
intuitive access to complex systems models otherwise inaccessible. SiViT is able to 
represent graphically the network structure of models of cell signalling, such as 
that described in Figure 1. The models encapsulate a system of differential 
equations and SiViT computes these equations and animates a simulation of the 
model the system dynamics. Thus SiViT provides a ‘movie’ of the simulation, 
showing the whole system behaviour. Moreover, each node in the network can be 
queried and a pop-up graph of node activity over time presented.  
 
This is a useful contribution in respect of validation: all models depend on a set of 
assumptions and these assumptions can be difficult to elicit, especially in the case 
of complex systems models. Modelling frameworks such as CoSMoS (Bown et al. 
2012) have found ways of explicating and then challenging the assumption set 
underpinning a complex systems model and its simulation. SiViT provides a 
complementary explication: simulation dynamics are animated in the hope that 
major departures in the model (or indeed simulation) formulation are identified. 
 
Crucially, SiViT also allows the user to add in and then visualise the effects of 
cancer-causing mutations and anti-cancer drugs. Mutations associated with drug 
resistance can be introduced by changing simulation parameters through another 
drop down menu. Drugs can be added in through a drop-down menu, at a 
prescribed dosage at a particular time. Combinations of drugs can be added to 
explore the effects of different doses and of dose sequencing. These combinations 
can be drawn from a known set of drugs. Alternatively, new drugs can be 
designed by changing simulation parameters directly to simulate the effect of that 
designed drug. 
 
Any simulation configuration, in terms of drugs and mutations can be compared 
with another (one) simulation configuration. In pairwise comparisons, the two 
configurations are defined as Control and Experiment and the visualisation is a mix 
of red, blue and white. The colour of each node and edge component is set by 
whether the value of the Control component is greater than, less than or equal to 
the value of the corresponding component in the Experiment, with colour intensity 





Figure 3: a signaling network visualisation with a pop-up dialogue box (Inset 1, 
bottom right) for amending drug regime and mutational status together with an 
inset with magnified detail (Inset 2, bottom left) taken from Bown et al. (2016). See 
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=
article&op=view&path%5B%5D=8747 for figures and related movies. 
 
 
Figure 4 shows a typical set of SiViT visualisations. The network is that of the 
PI3K/PTEN/AKT and RAF/MEK/ERK pathways shown in Figure 1 (except for the 
sub-network of Figure 1 below the ERK—pERK—ppERK interactions). Figure 4A 
and 4B show the effect of an anti-cancer drug after 1 minute and 10 minutes 
respectively. Figure 4A shows an immediate and substantial down-regulation of 
signalling since most of the network is blue. By 10 minutes, we observe differences 
in pathway dynamics: in Figure 4B the lower pathway is still down-regulated and 
the upper pathway has similar levels of signalling to the network without the drug, 
i.e. the Control condition, since much of this pathway is white. Thus, the overall 
signalling activity in this upper pathway is the same but signalling dynamics are 
slowed by the drug action – a different dynamic to that of the lower pathway. 
Areas in red show non-local, emergent phenomena: red areas represent 
accumulations of species concentrations as a result of drug action inhibiting nodes 
elsewhere in the pathway network.  
 
Figure 4C shows a network with a cancer-causing mutation introduced at a single 
point. This single point mutation has a marked effect on whole network 
functioning, where at the end of the 10-minute time-course the inhibitor has a far 
weaker effect in reducing signalling. Figure 4D depicts the state of the network 
after the use of combination therapy to restore network sensitivity to the drug. The 
resistant network with combination therapy shown in Figure 4D is very similar to 
the sensitive (normal) network with single therapy in Figure 4B in respect of the 
overall pattern of signalling. 
 
Note, the white insets show key biological indicators of signalling activity in the 
Control (black line) and Experiment (blue line) simulation conditions. In Figures 4A, 
4C and 4D the insets show AKT levels – a key regulator of cell survival, growth and 
proliferation. The intended drug action is to reduce the amount of active AKT in 
the network. In Figure 4A levels of inactive AKT are increased following drug action 
as expected; in the resistant network of Figure 4C inactive AKT is decreased. In 
Figure 4D, SiViT was used to determine the minimum dose to match the key 
biological indicator (AKT) as shown in the overlapping blue and black lines of the 
pop-up inset. 
 
Beyond this representation, the observer is currently left to construct an 
interpretation of the system dynamics by integrating the observed individual 
components; the task is of course easier than such inference from the equation set 
or graph-based time-series readouts. Additional layers of abstraction and 




Figure 4: SiViT visualisations of cell signalling (adapted from Bown et al. 2016). 
Figure 3A and 3B show the effect of an anti-cancer drug after 1 minute and 10 
minutes respectively. Figure 3C shows a network with a cancer-causing mutation 
introduced at a single point. Figure 3D shows the same network as Figure 3C but 
with combination therapy to overcome resistance. See 
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=






SiViT can reveal system dynamics in a literal sense. A key limitation of many 
information visualisation systems identified by (Lee et al. 2015) is that there is no 
provision for the “making of a story”. Where visualisations cue key events in the 
system dynamics, or story pieces, it is down to the user to extract and organise 
meaningfully those story pieces without support from the visualisation system (Lee 
et al. 2015). Additionally, visualisations are not typically designed to highlight key 
events, including system changes in functioning and – here – the invocation of 
compensatory mechanisms of feedback. 
 
For signalling networks, in the light of increasing understanding of the limitations 
of drug design targeting single nodes in the face of topological changes in 
signalling network architecture, Behar et al. (2013) propose that signalling hub 
topology, and crucially the response of that topology to differing signalling 
pathway inputs i.e. drugs, has utility in advancing anti-cancer therapy. In Behar et 
al. (2013) the network is viewed in terms of sub-networks that provide dynamical 
mapping of inputs to outputs; interventions (drugs) are viewed in terms of their 
impact on that mapping. They combine this concept with that of a network motif 
(Wong et al. 2011), where a motif is a particular configuration of nodes in a sub-
network that is observed regularly and pervasively in a range of biological systems. 
Motifs include switches, feedback loops, feed-forward loops and integrators. Behar 
et al. (2013) suggest that signalling networks either exhibit these motifs explicitly or 
may be abstracted into such a motif based on the observed dynamics of that sub-
network. In taking this view the network, or at least sub-networks, in addition to 
the pathway nodes, has agency. Moreover, motifs and changes in network or sub-
network topology may well represent key story pieces. 
 
Thus any interactive, visual account of cell signalling in response to drugs needs to 
reveal both node and sub-network dynamics, in an integrated and concurrent 
manner. System-scale dynamics must be portrayed such that conformational 
changes in sub-networks, such as from e.g. a feedback into a feed-forward loop, 
are depicted concurrently with up- and down-regulation of nodes, and 
importantly how the two are connected. This interconnection is likely to be non-
linear and context-sensitive: we must explore the use of concurrent accounts of 
signalling at different spatial and temporal scales to reveal this link, with key events 
in each account being cross-linked to reveal how one impacts the other. 
 
This dynamic representation of signalling network dynamics requires 
communication via video, and while highlighting important events is not readily 
translated into a narrative form. New work by Bach et al. (2016) provides a thought 
provoking first study on the use of the well-established and visually rich medium of 
comics to tell stories about dynamic networks. Bach et al. (2016) note that comics 
are already used to convey information beyond entertainment in order to inform 
and educate in an engaging way. They founded their notational design on good 
practice in the existing domain of graphic comics and tested the effectiveness of 
designed comics to convey network changes over time. The results confirmed that 
with minimal textual cueing the intended dynamics were successfully conveyed. 
 
While the comics used in this study are not as complex as required to represent 
signalling network dynamics, we believe that this work, combined with our own 
interactive and executable visualisation technology, provides a first hint towards 
the narrating of cellular signalling networks. In principle, and with some user 
direction, key switches in behaviour driven by drug action and mutation identified 
via SiViT could be pushed out to a comic format with panels showing key states 
and alternate pathways in time. The comic would then architect the key story 
pieces, and events leading to marked changes in signalling network functioning, 
into a narrative underpinned by the more detailed SiViT visualisation. This would 
both aid understanding of signalling network dynamics and, crucially, improve 
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